Liquidia Corporation (LQDA)
NCM · Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited
Recent press releases
Liquidia Corporation has not issued a press release in this window.
SEC filings
All filings →Liquidia Corporation has not filed an SEC document in this window.
Insider trades
All insider trades →Liquidia Corporation has no reported insider trades in the last 90 days.